Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia

Cell Rep. 2013 Oct 17;5(1):51-60. doi: 10.1016/j.celrep.2013.08.037. Epub 2013 Oct 3.

Abstract

Chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias are characterized by the t(9;22) chromosome, which encodes the BCR/ABL oncogene. Multiple mouse models of CML express BCR/ABL at high levels from non-Bcr promoters, resulting in the development of leukemias. In contrast, a significant fraction of healthy humans have been found to have BCR/ABL-positive hematopoietic cells. To bridge the gap between the information derived from current mouse models and nonleukemic humans with the BCR/ABL oncogene, we generated a knockin model with BCR/ABL p210 expressed from the Bcr locus. Unlike previous models, expression of BCR/ABL from the knockin allele did not induce leukemia. BCR/ABL mutant cells did exhibit favorable bone marrow engraftment compared to control cells. These data suggest that BCR/ABL expression alone is insufficient to induce disease. This model allows for inducible spatial and temporal control of BCR/ABL expression for analysis of early steps in the pathogenesis of BCR/ABL-expressing leukemias.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Animals
  • Bone Marrow Transplantation / methods*
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / metabolism
  • Fusion Proteins, bcr-abl / analysis
  • Fusion Proteins, bcr-abl / biosynthesis*
  • Fusion Proteins, bcr-abl / genetics*
  • Gene Expression Regulation
  • Gene Knock-In Techniques
  • Humans
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / metabolism
  • Mice
  • Mice, Transgenic

Substances

  • Fusion Proteins, bcr-abl